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Abstract
Background: Advanced HIV infection can result in lipoatrophy and wasting, even in the absence of ongoing
opportunistic infections, suggesting that HIV may directly affect adipose tissue amount and distribution.
Methods: We assessed the relationship of fat (measured using anthropometry, DEXA, MRI scans) or markers related
to glucose and lipid metabolism with viral load in a cross-sectional sample of 83 antiretroviral-naïve HIV-1-infected
South African women. A multivariable linear model was fitted to log10VL to assess the combined effect of these
variables.
Results: In addition to higher T cell activation, women with viral load greater than the population median had
lower waist circumference, body mass index and subcutaneous abdominal fat, as well as lower serum leptin. We
demonstrate that leptin serum levels are inversely associated with viral replication, independent of the amount of
adipose tissue. This association is maintained after adjusting for multiple variables associated with disease
progression (i.e., cellular activation and innate immunity effector levels).
Conclusions: Our results demonstrate that serum leptin levels are inversely associated with viral replication,
independent of disease progression: we postulate that leptin may affect viral replication.
Background
Progressive HIV infection [1,2] leads to loss of body fat,
altering subjects’ appearance and resulting in social
stigma and negative body image, particularly in women
[3]. Caloric intake and adiposity are regulated by adipo-
kines, neurotransmitters, hormones and their receptors
that modulate appetite, fat metabolism and energy
homeostasis [4]. Leptin is produced by adipocytes, and
contributes to appetite reduction via a negative hypotha-
lamic feedback [5], as well as exerting immunomodula-
tory activity (e.g., inhibition of cell proliferation and
promotion of type 1 adaptive responses [6-8]).
A correlation between adipose tissue and leptin is
maintained in antiretroviral-treated HIV-infected indivi-
duals, independent of viremic status or disease stage
[9-12], even though leptin receptor expression and
phosphorylation are increased in peripheral blood
mononuclear cells [13]. A number of factors (chronic
fever, increased TNF-a and IL-6 levels, opportunistic
infections and other secondary causes [1,14,15]) have
been considered to contribute to fat loss in advanced
disease; however, a direct link to viral replication has
not been established.
Women account for more than 50% of HIV-1 prevalence
worldwide [16]. Here, we explore the relationship between
viral load, cellular activation, innate immunity effector
levels and adipose tissue-related measures in a cohort of
antiretroviral therapy (ART)-naïve South African women.
Methods
Study subjects
A cross-sectional convenience sample of 83 ART-naïve,
HIV-1 infected women without evidence of prior or
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Clinical Research HIV-1 Unit, Themba Lethu Clinic
(University of the Witwatersrand, Johannesburg, South
Africa). Screening CD4+ T cell count was 200-350 cells/
mm
3. Medical history was obtained from the clinic
record and by interview. Informed consent was obtained
from all participants as per University of the Witwaters-
rand Ethics Committee and Wistar Institute IRB-
approved study protocol.
Flow cytometry
CD4+ T cell counts were assessed using the single plat-
form method described by Scott and Glencross [17].
Expression of lineage, differentiation and activation mar-
kers on CD3+ T cells (CD4, CD8, CD38, CD95, HLA-
DR, CD28), CD3- NK cells (CD16, CD56, HLA-DR) and
Lin-1
- Dendritic cells (Lin-1, HLA-DR, CD123, CD11c)
was assessed on whole peripheral blood using lyophi-
lized mAb panels (BD Biosciences, Palo Alto, CA). Sam-
ples were tested using a Faxcalibur Analyzer, followed
by analysis using CellQuest software (BD Biosciences).
Adipose tissue measurements
Body mass index (BMI) was calculated as weight (kg)/
height (m)
2. Dual Energy X-ray Absorptiometry (DEXA)
scans were performed using a Hologic QDR-2000 scan-
ner, assessing limb and trunk fat and lean mass. Bone
mineral density (g/cm
2) was also measured.
Magnetic resonance imaging (MRI) scans were per-
formed using a Toshiba Flexart 0.5 T; a single L4-L5
axial section was analyzed. Variables collected were
sagittal diameter, visceral, subcutaneous abdominal and
perirenal fat. The analysis was conducted using
V3.51*R553 software.
Clinical laboratory testing
Serum from fasting blood draws was tested for:
￿ Leptin: ELISA, BioVendor Laboratory Medicine,
Inc, Czech Republic
￿ High density lipoprotein (HDL)- and low density
lipoprotein (LDL)-associated cholesterol, triglycerides,
glucose: Roche Integra analyzer 400, Roche Diagnos-
tics, Mannheim, Germany
￿ Insulin: Immulite 1000 analyzer Diagnostics Corp,
Los Angeles. CA
￿ Proinsulin: ELISA, Dako-Cytomation Ltd (UK)
￿ Free fatty acids (FFA): half-micro test, Roche Diag-
nostics, Mannheim, Germany
￿ HIV-1 infection (confirmation): rapid antibody test-
ing and/or Ultra-sensitive (US) PCR, (Roche COBAS
Ampliprep/COBAS Amplicor v1.5 methods)
￿ Homeostatic Model Assessment for insulin resis-
tance (HOMA2-IR) was determined using the
HOMA2 calculator, v. 2.2, from the Diabetes Trials
Unit, University of Oxford, GB http://www.dtu.ox.ac.
uk/homa.
Statistical analysis
Study subjects were divided into two groups: Group 1
(low viral load, LVL): 41 subjects, viral load (VL) < sam-
ple median; and Group 2 (high viral load, HVL): 42
subjects, VL ≥ sample median. Differences in means
between groups for each of the variables listed in
Table 1 were tested using two-sample t-tests. Corre-
sponding p-values and q-values based on the positive
false discovery rate (FDR) are reported; q-values of less
than 0.2 were considered meaningful. Pairwise correla-
tions were tested by determining the Pearson correla-
tion coefficient (r).
The effect of selected variables on log10VL (univariate
analysis) was assessed by fitting a linear model using the
least square method. Additionally, a multivariable linear
model was fitted to log10VL using a step-wise approach
based on likelihood ratio tests [18]. For the final model,
Wald test statistics with p-values < 0.1 were considered
relevant. Goodness-of-fit was evaluated based on the
adjusted coefficient of determination (R
2): briefly, vari-
ables were added individually to the model, and those
v a r i a b l e st h a td i dn o tl e a dt oa ni n c r e a s eo fR
2 were
rejected. All statistical tests were performed using r vers.
2.10.0 ("the r Foundation for Statistical Computing”,
http://www.r-project.org/).
Results
Cohort clinical and immunological characterization
Eighty-three HIV-1-infected, ART-naïve women, aged 19
to 55 (mean age 34.5 years, see Table 1), and of black
(n = 81) or mixed race (n = 2) were studied. The cohort
median serum HIV RNA (VL) was 60,400 copies of HIV
RNA/ml (log10VL = 4.78; IQR = 1.21). Based on BMI,
our cohort was composed of three underweight (BMI <
18.5 kg/m
2), 33 normal weight (BMI 18.5-24.9 kg/m
2), 26
overweight subjects (BMI 25-29.9 kg/m
2)a n d2 0o b e s e
subjects (BMI > 30 kg/m
2), in keeping with prior reports
on similar South African cohorts [19]. The cohort mean
CD4+ T cell count was 260 cells/mm
3, indicative of mod-
erately advanced disease. Due to enrolment restrictions
of 200-350 CD4+ T cell count/mm
3,e n t r yC D 4 +Tc e l l
counts were only slightly lower in HVL (Table 1) than
LVL subjects. However, confirming previous reports
[20,21], cellular activation was higher in HVL subjects, as
assessed by the expression of CD38 on CD4+ and CD8+
T cells, and of HLA-DR on CD4+ T cells (Table 1). Like-
wise, we did not detect significant differences in the levels
of mature or activated NK cells, or of plasmacytoid
(PDC) or myeloid (MDC) dendritic cells.
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HVL women had lower BMI and waist circumference
than LVL women (Table 1). Direct MRI assessments of
abdominal fat content confirmed that HVL subjects had
considerably less subcutaneous abdominal fat than LVL
women, but similar amounts of visceral and perirenal fat
(Table 1). HVL women also had slightly lower DEXA
scan-based fat and lean mass measurements than LVL
women, but only trunk fat mass reached the level of sig-
nificance, confirming that the difference in adipose tis-
sue between HVL and LVL women is due to differential
representation of central fat. Bone density was similar in
the two groups (not shown).
We tested a number of markers associated with fat and
glucose regulation (Table 1); of all the indicators assessed,
only leptin levels were significantly lower in HVL subjects.







Variables Units N Mean SD N Mean SD N Mean SD unadjusted p * FDR q**
Age years 83 34.5 8.2 42 34.7 8.4 41 34.3 8.2 0.85 0.86
log10VL c/ml 83 4.5 0.8 42 5.2 0.3 41 3.9 0.6 n/a n/a
Immunology markers:
CD4+ T cell count cells/mm
3 83 260.8 53.9 42 249.0 50.7 41 272.9 54.9 0.04 0.14
CD8+ T cell count cells/mm
3 59 814.0 484.0 29 874.6 560.8 30 755.4 397.1 0.35 0.51
% CD38
+ CD4+ T cells % of CD4 60 75.5 11.3 30 79.0 9.0 30 72.0 12.3 0.02 0.1
% CD38+ CD8+ T cells % of CD8 60 87.0 11.2 30 91.1 7.8 30 82.8 12.6 0.0034 0.1
% HLA-DR+ CD4
+ T cells % of CD4 60 26.25 9.71 30 29.5 10.04 30 23.0 8.3 0.0090 0.1
% HLA-DR+ CD8
+ T cells % of CD8 60 56.4 14.3 30 59.6 14.6 30 53.2 13.4 0.08 0.1
% CD95+ CD4+ T cells % of CD4 60 78.5 10.9 30 80.6 10.9 30 76.4 10.6 0.13 0.28
% CD95+ CD8+ T cells % of CD8 60 60.6 7.2 30 60.4 6.1 30 60.8 8.3 0.84 0.86
% CD28+ CD4
++T cells % of CD4 60 80.7 11.1 30 80.1 10.7 30 81.2 11.7 0.70 0.82
% CD28+ CD8+ T cells % of CD8 60 30.8 9.3 30 30.3 9.7 30 31.3 9.1 0.68 0.82
Total NK cells cells/mm
3 59 12.9 10.2 29 14.4 12.9 30 11.5 6.6 0.28 0.46
% CD56+/CD16+ cells % of NK 60 54.9 20.1 30 50.4 18.8 30 59.4 20.6 0.08 0.1
% CD56+/CD16
- NK cells % of NK 60 22.1 16.2 30 23.4 17.6 30 20.9 14.9 0.55 0.74
% HLA-DR
+ total NK cells % of NK 60 19.9 16.8 30 22.2 17.9 30 17.6 15.6 0.29 0.46
% HLA-DR+ CD56+/CD16+ NK cells % of NK 60 23.0 20.8 30 26.2 22.7 30 19.7 18.6 0.23 0.4
Plasmacytoid dendritic cells cells/mm
3 58 0.2 0.1 28 0.1 0.1 30 0.2 0.1 0.18 0.37
Myeloid dendritic cells cells/mm
3 59 0.5 0.8 29 0.5 0.6 30 0.5 1.0 0.86 0.86
Adipose tissue-associated variables:
Body mass index (BMI) kg/m
2 82 27.4 7.1 41 25.6 6.4 41 29.2 7.4 0.02 0.1
Waist circumference cm 83 83.9 14.9 42 80.2 13.4 41 87.6 15.5 0.02 0.1
Subcutaneous abdominal fat (MRI) cm
2 81 338.8 195.9 42 294.2 185.9 39 386.9 197.3 0.03 0.12
Visceral abdominal fat (MRI) cm
2 81 51.5 30.4 42 47.3 28.8 39 56.1 31.9 0.20 0.37
Perirenal hilar fat (MRI) cm
2 81 5.7 3.1 42 5.5 3.4 39 6.0 2.8 0.40 0.56
Total fat mass (DEXA) kg 80 26.2 12.2 41 24.1 11.9 39 28.5 12.2 0.11 0.28
Total lean mass (DEXA) kg 80 40.9 5.9 41 39.8 54.4 39 42.1 6.1 0.09 0.26
Leg fat mass (DEXA) kg 80 11.6 5.6 41 10.8 4.5 39 12.5 6.5 0.20 0.37
Trunk fat mass (DEXA) kg 80 10.4 6.1 41 9.4 6 39 11.5 6 0.03 0.12
Weight kg 83 70.2 17.9 42 67.2 17.1 41 73.2 18.3 0.12 0.28
Reported weight loss % true 83 38 n/a 42 40 n/a 41 36.7 n/a 0.86*** 0.86
Leptin ng/ml 66 28.3 17.6 33 23.4 17.7 33 33.3 16.3 0.02 0.1
Triglycerides mmol/l 77 0.9 0.4 38 0.9 0.3 39 0.9 0.4 0.57 0.74
LDL-associated cholesterol mmol/l 77 2.3 0.8 38 2.2 0.6 39 2.3 0.9 0.62 0.78
Free fatty acids mmol/l 66 0.5 0.2 33 0.5 0.2 33 0.4 0.3 0.31 0.47
Glucose mmol/l 74 4.3 0.4 37 4.3 0.4 37 4.3 0.4 0.75 0.85
HOMA2-IR n/a 67 0.9 0.5 32 0.8 0.4 35 1.0 0.6 0.10 0.27
* based on two-sample t-test
** false discovery rate. q values < 0.2 were considered significant
*** Chi square test
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BMI (r = 0.6991; p < 0.0001), MRI-measured subcuta-
neous (Figure 1) or visceral abdominal fat (r = 0.7755
and 0.5417, respectively, both p < 0.0001) or DEXA-
based total fat mass, (r = 0.7637; p < 0.0001)].
Unlike direct measures of adiposity, serum lipids and
glucose were similar in HVL and LVL women.
Visceral fat was positively associated with levels of
insulin (r = 0.3861, p = 0.0010), C-peptide (r = 0.5331, p
< 0.0001) and HOMA2-IR (r = 0.2774, p = 0.0241), but
not proinsulin/insulin ratio; similar results were
obtained for subcutaneous abdominal fat. Reported
recent weight loss rates and free fatty acids (FFA) levels
were similar in both groups (Table 1), and FFA showed
no association with the amount of adipose tissue
(r = 0.1084, p = 0.3868).
Modelling of leptin levels as a predictor of viral load,
independent of fat accumulation
To determine the relationship between metabolic para-
meters and viral replication, we first assessed the rela-
tionship of all individual variables (see Table 1) with
log10 VL by fitting a linear model using all available
data points (i.e., no censoring of subjects missing indivi-
dual variable measurements). As illustrated in Table 2
and Figure 2, of the 35 variables tested, only eight had a
significant (p < 0.05) effect on log10VL based on uni-
variate analysis. As expected, the direction of this effect
was positive for parameters associated with activation
(CD4+ T cells expressing CD38 or HLA-DR, CD8+
T cells expressing CD38), indicating that subjects with
higher viral load also have higher cellular activation.
Conversely, a negative effect was observed for PDC
counts, mature NK cell frequency, as well as BMI, sub-
cutaneous abdominal fat and leptin (Figure 2), support-
ing the observations of differences between HVL and
LVL women, as we have described. Importantly, the
negative association between leptin serum levels and
log10VL was maintained (n = 65; effect estimate =
-0.0186653; p = 0.0289), even after adjusting for subcu-
taneous abdominal fat area in multivariate analysis, sup-
porting a direct association between leptin levels and
viral replication, independent of the amount of adipose
tissue.
Figure 1 Association of serum leptin levels with subcutaneous fat. Linear regression modelling of the association between observed serum
leptin levels and MRI-assessed subcutaneous fat area. Circles represent individual observations. P < 0.0001; adjusted R
2 = 0.5983.
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log10VL were further tested in a subset of subjects with
complete datasets (no missing variable measurements; n
= 45). Based on their ability to improve the model pre-
dictivity (as assessed by testing the model likelihood
ratio), five significant variables were selected to build
the additive model: the estimate terms for the model
and corresponding test statistics are provided in Table
3. Leptin levels, mature NK frequency and PDC count
have a negative effect on log10VL that were significant
Table 2 Variable association with log10VL, univariate analysis*
Predictor n Effect estimate SE Pr(>|t|) Adjusted R
2
% CD56+/CD16+ NK cells 60 -0.005 0.005 0.0048 0.1140
% HLA-DR+ CD4+ T cells 60 0.020 0.009 0.0358 0.0092
% CD38+ CD4+ T cells 60 0.020 0.009 0.0358 0.0578
% CD38+ CD8+ T cells 60 0.025 0.009 0.0091 0.0964
Plasmacytoid dendritic cells 58 -1.718 0.814 0.0392 0.0572
Leptin 66 -0.003 0.005 0.0130 0.0784
Subcutaneous abdominal fat (MRI) 81 -0.001 0.0004 0.0400 0.0403
Body mass index (BMI) 82 -0.025 0.012 0.0403 0.0397
* linear model fitting, least squares method
Figure 2 Association of metabolic and immunologic parameters with HIV viral load. Linear regression modelling of the association
between log10 serum viral load and significantly associated variables; individual p values and adjusted R
2 for the associations are indicated.
Circles represent individual observations.
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expression of CD38 on CD8+ T and HLA-DR on CD4+
T cells was not significant. Taken together, our analysis
indicates that leptin levels, together with mature NK
and PDC frequency, remain negatively associated with
log10VL after adjustment for multiple metabolic and
activation parameters, suggesting an independent
association.
Discussion
W es h o wf o rt h ef i r s tt i m et h a tl e p t i nl e v e l sa r ea s s o -
ciated with viral load after adjusting for fat measure-
ments. Body fat changes in HIV-infected individuals
have been the subject of a number of studies, many of
which have focused on ART-associated lipodistrophy
[22-26]. Yet to our knowledge, no study has directly
sought to determine the relationship between fat, leptin
and HIV replication. Importantly, since opportunistic
infections (OIs), in association with lower CD4+ T cell
count, might also contribute to low adiposity in chronic
HIV infection (via LPS-induced TNF, limited food
intake, malabsorption, etc.), we chose to study OI-free,
A R T - n a ï v ew o m e nw i t h i nan a r r o wC D 4 +Tc e l lc o u n t
range (200-350 CD4+ T cell count/mm
3 at screening);
however, a contribution of prior or subclinical OIs and
other potential confounding factors cannot be categori-
cally excluded.
The narrowness of the cohort’s CD4+ T cell count
range (which limits the confounding effects of this vari-
able) might explain the observed lack of a significant
effect of CD4+ T cell count levels on VL, which has
been consistently reported in larger, unrestricted cohorts
[27]. However, as expected, in our cohort, viral load was
positively associated with immune activation (CD38 and
HLA-DR expression) and negatively associated with the
frequency of innate immunity effectors (PDC and
mature NK cells) in peripheral blood, confirming prior
observations [28-32].
HVL women showed lower BMI, waist circumference
and subcutaneous abdominal fat than LVL women, with
a significant negative association between VL and sev-
eral measures of central fat. Leptin levels observed in
LVL women were similar to those observed in a cohort
of 50 healthy women with similar age, ethnicity and pro-
venance (median BMI 27 kg/m
2,I Q R1 0 . 8 5 ;m e d i a n
serum leptin 36.15 pg/ml, IQR = 38.95, N Crowther,
unpublished results).
As predicted by the fact that leptin is mainly produced
by subcutaneous fat adipocytes [33], this adipokine was
also lower in HVL women, and its levels are inversely
correlated to viral replication. Interestingly, however,
HOMA2-IR, another marker usually highly correlated
with adiposity, presented no association with VL in our
cohort, and was only weakly associated with leptin levels
(p = 0.0751). Taken together, these results indicate that:
(a) adipose tissue is associated with both leptin levels
and insulin resistance; and (b) only leptin levels are
inversely associated with viral replication, suggesting the
hypothesis that the inverse relationship between viral
replication and leptin levels may be independent of the
amount of adipose tissue. Formal testing of this hypoth-
esis in a multivariate model demonstrated that the effect
of leptin is in fact independent of direct measures of fat
(e.g., subcutaneous fat area).
With the exception of leptin, serum molecules asso-
ciated with adipose tissue and obesity (e.g., total or LDL
cholesterol, triglycerides, glucose, insulin) did not inde-
pendently correlate with VL in our cohort, in contrast
with prior reports that VL could predict BMI in HIV-
infected women [2], and correlate negatively with LDL
and HDL cholesterol and positively with triglycerides,
but not with insulin or glucose levels [34,35]. Indeed, we
confirmed the selection of leptin over any other adipose
tissue measure that appeared to be individually corre-
lated with log10VL by introducing BMI or subcutaneous
abdominal fat in a multivariate model with leptin:
neither carried a significant independent association
(p = 0.3667 and 0.884, respectively), and both actually
resulted in making our model less accurate by reducing
the adjusted R
2 (0.063 and 0.05, as compared to 0.066
for leptin alone).
Therefore, among measures and correlates of adipose
tissue, leptin remained the variable best associated with
viral replication, suggesting the possibility that leptin
may play a role in the observed significant association
between fat and viral replication. Interestingly, prior stu-
dies (FRAM cohort [36]) testing whether viral replica-
tion was associated with serum adipokines did not
evidence a significant association between adiponectin
and leptin levels and HIV viral load: the fact that our
cohort is composed only of ART-naïve women with a
narrow CD4 range, and possibly the high levels of




SE T value Pr (>|t|)
Intercept 3.896921 0.839040 4.644 <0.0001
% CD56+/CD16+ NK cells -0.009494 0.005328 -1.782 0.0826
Leptin -0.011514 0.005597 -2.057 0.0464
Plasmacytoid dendritic cells -2.801874 1.147009 -2.443 0.0192
% HLA-DR+ CD4+ T cells 0.017391 0.010856 1.602 0.1172
% CD38+ CD8+ T cells 0.016283 0.009788 1.664 0.1042
Residual standard error: 0.6274 on 39 degrees of freedom
Multiple R-squared: 0.4301, Adjusted R-squared: 0.357
F-statistic: 5.877 on 5 and 39 DF, p-value: 0.0003816
* The final model is an additive model with main effects for each of the terms
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discordance.
Based on leptin’s known immunomodulatory activity
[6-8,13,37,38], it is interesting to speculate that in HVL
women, lower leptin levels may contribute to chronic
immune activation, in keeping with the observed
increased expression of CD38 and HLA-DR in T cell
subsets. Obesity is associated with chronic low-level
inflammation and high levels of TNF-a [39], which is
produced by subcutaneous adipocytes [40]. This condi-
tion would be expected to promote viral replication
since TNF-a promotes HIV replication via NFB activa-
tion [41].
The negative association between leptin and viral
replication that we report here suggests that leptin,
which is produced by adipocytes in response to expo-
sure to TNF-a[42], may be part of a negative regulatory
feedback that attenuates the pro-inflammatory and pro-
replicative effects of TNF-a. Interestingly, this effect is
likely lost in chronic inflammatory conditions where a
negative association between TNF-a and leptin produc-
tion has been observed [43,44]. Conversely, increased
body fat may attenuate viral load via the effects of other
mediators (e.g., MIP-1a) known to suppress HIV infec-
tion [45]). Another potential mechanism could be that
high viral replication and cellular activation may result
in chronic inflammation, affecting adipocytes and caus-
ing lipoatrophy and lower leptin levels.
The interpretation of these results should be qualified
in light of the cross-sectional design of the study, which
does not allow the interpretation of cause-effect rela-
tionships in the variables studied. Further longitudinal
studies focusing on these factors will be required to
determine whether fat changes directly contribute to
alterations in viral replication via adipocyte-mediated
leptin secretion.
Conclusions
Our data provide the first demonstration of a relation-
ship between VL and leptin in African women and
suggest that lower leptin levels associated with the
loss of adipose tissue may contribute to disease
progression.
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